$Supernus Pharmaceuticals (SUPN.US)$ Supernus Pharmaceutical...

Supernus Pharmaceuticals agreed to acquire Adamas Pharmaceuticals for $8.10 a share in cash, or about $400 million, for two drugs approved for use in patients with Parkinson's disease. The transaction also includes two contingent value rights (CVR) with a total value of $1 per share in cash, or approximately $50 million. The initial cash consideration represents a premium of about 75% to Adamas' Oct. 8 closing share price.